Abstract:INTRODUCTION: Immune checkpoint inhibitors (ICI) in metastatic melanoma results in durable responses in ∼50% of patients. Our understanding of the tumour immune microenvironment (TME) features underpinning ICI response or resistance is currently incomplete. METHODS: To address this issue, we explored the TME of melanoma lymph node metastases (MLN mets) at a spatial (n = 32) and a single cell level (n=24). MLN mets were either from ICI-responder and ICI-resistant patients or untreated controls. We used multiplex IHC and our SPIAT algorithm to examine the spatial immune context of the TME, and also analyzed gene expression by RNAseq. Cells were also isolated from fresh tissue before or after ICI and analyzed by single cell RNAseq and TCRseq to derive high dimension data on T cells and their clonality, all other immune and melanoma cells. Finally, we performed cell-cell interactome and neighborhood analyses to reveal which cell and molecular interactions were associated with response. RESULTS: In patients who responded to ICI, both CD4+ and CD8+ tissue resident memory (TRM) T cell subset density were significantly increased within the tumor, and this correlated with closer distance to melanoma cells. (p<0.05). Single cell data revealed multiple clusters of immune cells (T, B, NK, Mø, DC) and melanoma cells. CD8+ T cell clustering revealed heterogeneous differentiation states. In ICI responders, we observed enrichment for TRM with an earlier transcriptional profile (TCF1+ Tpex.TRM and early TEM.TRM) and lower expression of the exhausted T cell (Texh) gene signature (p<0.05). Hyperexpanded CD8+ T cell clones were present in the TRM cell cluster and were enriched in the responder patients but not in those with resistant disease. CD4+ T cells showed both TRM and TFH clusters with shared expression of multiple genes, with CD4+ TRM also expressed a cytotoxicity gene module. Additionally, Mø and melanoma cells in resistant disease had significantly higher IFNg and IFN-I response gene expression levels compared to tumors from responders (p<0.05), suggesting that chronic activation of T cells in LN mets could lead to the observed Texh phenotype. Interactome analysis displayed putative interactions between CD4+ and CD8+ TRM via the CCL4-CCR5 axis in the ICI responders. This was confirmed by spatial analysis of neighborhood archetypes, which showed significantly increased cell-cell contact between both TRM subsets within the tumor of responders (p<0.05). Finally, conventional dendritic cells interact with both CD8+ and CD4+ TRM subsets in the tumor of responders, providing key signals for maintenance of the TRM pool within the tumor. CONCLUSIONS: MLN mets that respond to ICI are characterized by increased TRM comprising hyperexpanded TCR clones and complex TRM-containing neighborhood archetypes. Whilst these tumors show increased global inflammation, at a single cell level the resistant tumors have increased Texh and greater expression of IFN-regulated genes in melanoma cells and macrophages suggesting ineffective response to chronic antigen stimulation. Citation Format: Andrea Di Pietro, Lewis Au, Patrick Crock, Niko Thio, Angela Pizzolla, Marina Bacac, Ramona Schlenker, Aparna Rao, L Spain, David Gyorki, Shahneen Sandhu, Grant McArthur, Paul J Neeson. Tissue resident memory (TRM) T cells and dendritic cells form an in situ archetype for improved response to immune checkpoint therapy in metastatic melanoma [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr A006.

Dendritic cells maintain anti-tumor immunity by positioning CD8 skin-resident memory T cells

Dendritic cells instruct differentiation of tissue resident memory T cells in the skin to promote durable tumor immunity

Tissue-resident memory CD8+ T cells promote melanoma–immune equilibrium in skin

Tissue-resident memory CD8+ T cells amplify anti-tumor immunity by triggering antigen spreading through dendritic cells

Abstract A006: Tissue resident memory (TRM) T cells and dendritic cells form an in situ archetype for improved response to immune checkpoint therapy in metastatic melanoma

The role of tissue-resident memory T cells as mediators for response and toxicity in immunotherapy-treated melanoma—two sides of the same coin?

Abstract 3961: Impact of CD8 resident memory T cells on antitumor immunity and response to cancer immunotherapy

Resident memory T cells in tumor-distant tissues fortify against metastasis formation

Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy

Dysfunction of Dendritic Cells in Tumor-Draining Lymph Nodes

A Reservoir of Stem-Like CD8 T Cells in the Tumor-Draining Lymph Node Maintains the Ongoing Anti-Tumor Immune Response

Antitumor progenitor exhausted CD8 + T cells are sustained by TCR engagement

Dendritic cells dysfunction in tumor-draining lymph nodes

Divergent molecular networks program functionally distinct CD8 + skin-resident memory T cells

Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment

Tumor-resident memory T cells as a biomarker of the response to cancer immunotherapy

Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma

Tumour-retained activated CCR7+ dendritic cells are heterogeneous and regulate local anti-tumour cytolytic activity

Dendritic Cells in Shaping Anti-Tumor T Cell Response

TCF1-positive and TCF1-negative TRM CD8 T cell subsets and cDC1s orchestrate melanoma protection and immunotherapy response

CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses